Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | September 10, 2026 | September 14, 2026 |
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | EVP, Chief Research Officer | March 10, 2026 | March 12, 2026 |
| Translate Bio, Inc.TBIO · Entity 135439 | Director | September 14, 2021 | September 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,140 |
Reported balance
After 2026-09-10 transaction · row 1
1 source rowRow 1 · 2026-09-10 · Grant · Acquired 6,140 · Balance 6,140 F1: Restricted stock units granted on September 10, 2026. Price not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on September 10, 2026. Price not applicable.
BRISTOL MYERS SQUIBB CO
Report date March 10, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 21,528 |
Ending reported balance
After 2026-03-10 transaction · row 9
9 source rows · reconciled sequenceRow 1 · 2026-03-10 · Exercise / conversion · Acquired 1,107 · Balance 16,946 F1: Represents vesting of one-quarter market share units granted on March 10, 2022. Row 2 · 2026-03-10 · Other · Disposed 124 · Balance 16,822 F2: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Row 3 · 2026-03-10 · Tax withholding · Disposed 436 · Balance 16,386 F3: Shares withheld for payment of taxes upon vesting of awards. Row 4 · 2026-03-10 · Exercise / conversion · Acquired 2,342 · Balance 18,728 F4: Represents vesting of one-quarter market share units granted on March 10, 2023. Row 5 · 2026-03-10 · Other · Disposed 253 · Balance 18,475 F2: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Row 6 · 2026-03-10 · Tax withholding · Disposed 927 · Balance 17,548 F3: Shares withheld for payment of taxes upon vesting of awards. Row 7 · 2026-03-10 · Exercise / conversion · Acquired 14,052 · Balance 31,600 F5: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award. Row 8 · 2026-03-10 · Other · Disposed 6,900 · Balance 24,700 F6: Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board. Row 9 · 2026-03-10 · Tax withholding · Disposed 3,172 · Balance 21,528 F3: Shares withheld for payment of taxes upon vesting of awards. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2026-03-10 | Direct | 0 |
Reported balance
After 2026-03-10 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-03-10 · Exercise / conversion · Disposed 1,107 · Balance 0 F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F1: Represents vesting of one-quarter market share units granted on March 10, 2022. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2027-03-10 | Direct | 2,342 |
Reported balance
After 2026-03-10 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-03-10 · Exercise / conversion · Disposed 2,342 · Balance 2,342 F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F4: Represents vesting of one-quarter market share units granted on March 10, 2023. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2029-03-10 | Direct | 17,959 |
Reported balance
After 2026-03-10 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-03-10 · Grant · Acquired 17,959 · Balance 17,959 F11: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. F12: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2026-03-10 | Direct | 0 |
Reported balance
After 2026-03-10 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-03-10 · Exercise / conversion · Disposed 14,052 · Balance 0 F10: Each performance share unit converted into one share of common stock upon distribution in the first quarter of 2026. F5: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2029-03-10 | Direct | 26,939 |
Reported balance
After 2026-03-10 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-03-10 · Grant · Acquired 26,939 · Balance 26,939 F13: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBMS Savings and Investment Program | 3,026.38 |
Reported balance
Holding disclosure · report date 2026-03-10 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 3,026.38 F7: Based on recent 401(k) plan statement. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectFamily Trust | 200 |
Reported balance
Holding disclosure · report date 2026-03-10 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 200 F8: Shares held in a family trust, where reporting person is a beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents vesting of one-quarter market share units granted on March 10, 2022.
F2: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor.
F3: Shares withheld for payment of taxes upon vesting of awards.
F4: Represents vesting of one-quarter market share units granted on March 10, 2023.
F5: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award.
F6: Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board.
F7: Based on recent 401(k) plan statement.
F8: Shares held in a family trust, where reporting person is a beneficiary.
F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%.
F10: Each performance share unit converted into one share of common stock upon distribution in the first quarter of 2026.
F11: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout.
F12: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board.
F13: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board.
Translate Bio, Inc.
Report date September 14, 2021 · Filed September 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.36 · Expires 2029-04-09 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-09-14 · Sale · Disposed 37,800 · Balance 0 F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F2: This option was granted on April 10, 2019. The shares underlying this option are scheduled to vest and become exercisable in equal monthly installments, beginning on May 10, 2019 and ending on the three year anniversary of April 10, 2019. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.20 · Expires 2029-06-17 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-09-14 · Sale · Disposed 18,900 · Balance 0 F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F3: This option was granted on June 18, 2019. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.33 · Expires 2030-06-15 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-09-14 · Sale · Disposed 18,900 · Balance 0 F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F4: This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.43 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-09-14 · Sale · Disposed 20,000 · Balance 0 F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F5: This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
F2: This option was granted on April 10, 2019. The shares underlying this option are scheduled to vest and become exercisable in equal monthly installments, beginning on May 10, 2019 and ending on the three year anniversary of April 10, 2019.
F3: This option was granted on June 18, 2019. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2020.
F4: This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021.
F5: This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 02, 2023 Filed Dec 5, 2023 23:23 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 274 | $50.10 | $13,727.40 |
DisclosureSEC source: 0000014272-23-000195 · wk-form4_1701818599.xml · nonDerivative · entry 2 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,926 F2 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 23:23 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 616 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-23-000195 · wk-form4_1701818599.xml · nonDerivative · entry 1 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit vests in four equal annual installments beginning on December 2, 2020. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:24 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 732 | $61.14 | $44,754.48 |
DisclosureSEC source: 0000014272-23-000154 · wk-form4_1691443460.xml · nonDerivative · entry 1 Plenge Robert M · CIK 0001773367 · EVP, Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,584 F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $61.142 to $61.145, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 19:28 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $20.43 | $0.00 |
DisclosureSEC source: 0001209191-21-056055 · doc4.xml · derivative · entry 4 Plenge Robert M · CIK 0001773367 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · kind: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F5 · derivative.exercise_date: This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 19:28 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStock Option (right to buy) · Derivative | 18,900 | $0.00 Strike: $15.33 | $0.00 |
DisclosureSEC source: 0001209191-21-056055 · doc4.xml · derivative · entry 3 Plenge Robert M · CIK 0001773367 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,900 shares Expires 2030-06-15 F1 · kind: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F4 · derivative.exercise_date: This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 19:28 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStock Option (right to buy) · Derivative | 18,900 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001209191-21-056055 · doc4.xml · derivative · entry 2 Plenge Robert M · CIK 0001773367 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,900 shares Expires 2029-06-17 F1 · kind: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F3 · derivative.exercise_date: This option was granted on June 18, 2019. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2020. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 19:28 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStock Option (right to buy) · Derivative | 37,800 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0001209191-21-056055 · doc4.xml · derivative · entry 1 Plenge Robert M · CIK 0001773367 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,800 shares Expires 2029-04-09 F1 · kind: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F2 · derivative.exercise_date: This option was granted on April 10, 2019. The shares underlying this option are scheduled to vest and become exercisable in equal monthly installments, beginning on May 10, 2019 and ending on the three year anniversary of April 10, 2019. Read SEC document |
| June 16, 2021 Filed Jun 16, 2021 17:16 UTC | Translate Bio, Inc. TBIO · Entity 135439 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $20.43 | $0.00 |
DisclosureSEC source: 0001209191-21-040986 · doc4.xml · derivative · entry 1 Plenge Robert M · CIK 0001773367 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 20:09 UTC | Translate Bio, Inc. TBIO · Entity 135439 | GrantStock Option (right to buy) · Derivative | 18,900 | $0.00 Strike: $15.33 | $0.00 |
DisclosureSEC source: 0001209191-20-037131 · doc4.xml · derivative · entry 1 Plenge Robert M · CIK 0001773367 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,900 Underlying: Common Stock · 18,900 shares Expires 2030-06-15 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 16:25 UTC | Translate Bio, Inc. TBIO · Entity 135439 | GrantStock Option (right to buy) · Derivative | 18,900 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001209191-19-038022 · doc4.xml · derivative · entry 1 Plenge Robert M · CIK 0001773367 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,900 Underlying: Common Stock · 18,900 shares Expires 2029-06-17 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant. Read SEC document |
| April 10, 2019 Filed Apr 11, 2019 08:41 UTC | Translate Bio, Inc. TBIO · Entity 135439 | GrantStock Option (right to buy) · Derivative | 37,800 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0001209191-19-024329 · doc4.xml · derivative · entry 1 Plenge Robert M · CIK 0001773367 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,800 Underlying: Common Stock · 37,800 shares Expires 2029-04-09 F1 · derivative.exercise_date: The shares underlying this option are scheduled to vest and become exercisable in equal monthly installments, beginning on May 10, 2019 and ending on the three year anniversary of April 10, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.